Gene-Disorder Association · Article
Gene
MYC MYC Proto-Oncogene, BHLH Transcription Factor
×
First reported
1990
Supporting publications
17
Manually curated Approved treatment annotated
Association Review
In brief The association between MYC (MYC Proto-Oncogene, BHLH Transcription Factor) and Myeloma, Multiple is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
40
Compounds
1
Trials
69 of 1,604 via MYC compounds
Publications
17
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Myeloma, Multiple
The disorder 18 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features 34 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics 1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 1,604 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
17 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 15 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access